Olaparib, the first PARP inhibitor approved in the clinic has proven effective in the treatment of ovarian tumours characterized by BRCA1/2 mutations [5–7] and many other trials are ongoing to demonstrate the potency of other PARP inhibitors in BRCA1/2 tumours [8]. This evidence concerns the gene BRCA1 and neoplasm.